Cargando…
Arsenic in leukemia: A RSKy business
It has been known for many years that arsenic trioxide (As(2)O(3); ATO) is an effective therapy for acute promyelocytic leukemia but has little activity against other forms of the disease. ATO has diverse modes of action, but is well known to generate high levels of reactive oxygen species in cells...
Autor principal: | Dent, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926878/ https://www.ncbi.nlm.nih.gov/pubmed/24025257 http://dx.doi.org/10.4161/cbt.26159 |
Ejemplares similares
-
Business of medicine
por: Abdullah, BJJ
Publicado: (2010) -
The Business of RNAi Therapeutics in 2012
por: Haussecker, Dirk
Publicado: (2012) -
Business alignment for the “Decade of Action”
por: Sachs, Jeffrey D., et al.
Publicado: (2021) -
Arsenic, Organic Foods, and Brown Rice Syrup
por: Jackson, Brian P., et al.
Publicado: (2012) -
International business policymaking for a “wicked” world
por: Rašković, Matevž
Publicado: (2021)